Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.44 |
| ▸ | ABL2 | P42684 | 4/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | BCR | P11274 | 5/20 | 0.41 |
| ▸ | LYN | P07948 | 3/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449286 | 0.92 | ABL1 (0.39) | ABL1ABL2KITMAPK14 | |
| SCHEMBL24449230 | 0.91 | ABL1 (0.40) | ABL1ABL2CSF1RKITMAPK14 | |
| SCHEMBL24448273 | 0.86 | ABL1 (0.39) | ABL1ABL2DYRK1ACSF1RKIT | |
| SCHEMBL24448254 | 0.78 | ABL1 (0.70) | ABL1ABL2CSF1RKITMAPK14 | |
| SCHEMBL24449235 | 0.77 | ADORA1 (0.38) | ABL1ABL2DYRK1AGSK3BMAPK14 | |
| SCHEMBL24449122 | 0.77 | ABL1 (0.40) | ABL1ABL2GSK3BCSF1RKIT | |
| SCHEMBL24449234 | 0.75 | ABL1 (0.42) | ABL1ABL2MAPK14 | |
| SCHEMBL19316713 | 0.69 | ABL1 (0.45) | ABL1ABL2DYRK1AGSK3BMAPK14 | |
| SCHEMBL29614720 | 0.68 | MAPK14 (0.50) | ABL1ABL2BCRLYNCSF1R | |
| SCHEMBL19307120 | 0.68 | MAPK14 (0.50) | ABL1ABL2BCRLYNCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | ABL1 4516/4885ABL2 2755/4885DYRK1A 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.